Future research should validate biomarker thresholds (e.g., NT-proBNP, IL-6) for early detection and outcome prediction [19,20], and assess interventional strategies—such as fluid-balance optimization or cardio-protective therapies—to prevent APE and subsequent fibrosis [17]. The gene discussed is NPPB; the disease is apparent mineralocorticoid excess.